Abstract Number: 1717 • ACR Convergence 2024
Early Antimalarial Adherence Reduces Future Hospitalization Cost in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: Evidence from a Population-based Study
Background/Purpose: To examine the association between antimalarial (AM) adherence and hospitalization costs among newly diagnosed rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.Methods: We…Abstract Number: 1723 • ACR Convergence 2024
Clustering Analysis with Unsupervised Machine Learning Process to Phenotype the Cardiovascular Risk of Patients with Rheumatoid Arthritis Beyond the 10-year Prediction Algorithm
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased cardiovascular (CV) risk, but traditional CV risk factors and available 10-year CV risk estimation models may not…Abstract Number: 1906 • ACR Convergence 2024
Bayesian Algorithm to Identify Osteoarthritis in Administrative Health Data Without Requiring Chart Review
Background/Purpose: Osteoarthritis (OA) is the most prevalent arthritis and a significant contributor to Years Lived with Disability. Administrative health data are widely used to study…Abstract Number: 2400 • ACR Convergence 2024
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts
Background/Purpose: Nearly 20% of pregnancies in systemic lupus erythematosus (SLE) patients result in an adverse pregnancy outcome (APO); early identification of those at high APO…Abstract Number: 0157 • ACR Convergence 2024
Knowledge and Attitudes About Delta-9-tetrahydrocannabinol (THC) Impact Real-world Practice in an International Group of Rheumatologists
Background/Purpose: Rheumatologists care for difficult to manage chronic diseases, necessitating adjustments to new treatments and evolving patient views. When making treatment decisions, rheumatologists incorporate clinical…Abstract Number: 0657 • ACR Convergence 2024
Data-driven Bayesian Network Analysis for Predicting Difficult-to-treat (DTT) Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), with 14-33% failing to respond to standard treatments. This study assesses treatment…Abstract Number: 0724 • ACR Convergence 2024
Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) is a group of vasculitis that affect small vessels. Includes Granulomatosis with polyangiitis (GPA), Eosinophilic granulomatosis with…Abstract Number: 0735 • ACR Convergence 2024
ANCA-associated Vasculitis (AAV) and Long-term Risk of Cardiovascular Disease: Large-scale Propensity-matched Global Retrospective Cohort Study
Background/Purpose: In spite of significantly improved therapy during the last years, long-term morbidity and mortality has remained high in ANCA-associated vasculitis (AAV). The main causes…Abstract Number: 0796 • ACR Convergence 2024
Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases
Background/Purpose: England has seen a notable rise in prescription opioid use over the past two decades, leading to some of Europe's highest opioid-related hospital admissions.…Abstract Number: 1114 • ACR Convergence 2024
Nintedanib in Autoimmune Disease-related Interstitial Lung Disease: Real-life Effectiveness, Safety and Tolerance in a Spanish Multicenter Study
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of autoimmune diseases (AD). In recent years, new strategies for the treatment of progressive pulmonary fibrosis…Abstract Number: 0131 • ACR Convergence 2023
Identifying Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease: Development and Validation of a Real-Time Risk Model
Background/Purpose: Up to 20% of the general population has a positive ANA without having autoimmune disease. Currently, no tools exist to help clinicians interpret the…Abstract Number: 0132 • ACR Convergence 2023
Feasibility of a Real-Time Risk Model to Identify Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease
Background/Purpose: Positive antinuclear antibodies (ANAs) cause diagnostic dilemmas for clinicians across multiple specialties. We previously developed and validated a risk model using a de-identified electronic…Abstract Number: 0550 • ACR Convergence 2023
Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is linked to increased morbidity, mortality, and adverse health-related quality of life. Early disease, a history of NPSLE, aPL…Abstract Number: 0971 • ACR Convergence 2023
Network Meta Analyses of the Effectiveness and Safety Profiles of Janus Kinase Inhibitors and Biologic Agents in Treating Children with Non-systemic Juvenile Idiopathic Arthritis (nsJIA)
Background/Purpose: Tofacitinib (TOFA, NCT02592434) and Baricitinib (BARI, NCT03773978) are Janus kinase inhibitors (JAKi) that are approved for or being tested for nsJIA treatment. We aim…Abstract Number: 0978 • ACR Convergence 2023
Identifying Important Clinical Features for Predicting Remission in Patients with Rheumatoid Arthritis Treated with Biologics Using Machine Learning Model
Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) offer promising results for rheumatoid arthritis (RA) patients in general, but a substantial percentage of patients do not respond…
ACR Meeting Abstracts